M
Melody A. Cobleigh
Researcher at Rush University Medical Center
Publications - 150
Citations - 20396
Melody A. Cobleigh is an academic researcher from Rush University Medical Center. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 42, co-authored 142 publications receiving 19394 citations. Previous affiliations of Melody A. Cobleigh include Duke University & Pfizer.
Papers
More filters
Journal ArticleDOI
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
Charles L. Vogel,Melody A. Cobleigh,Debu Tripathy,John Gutheil,Lyndsay Harris,Louis Fehrenbacher,Dennis J. Slamon,Maureen E. Murphy,William Novotny,Michael Burchmore,Steven Shak,Stanford J. Stewart,Michael F. Press +12 more
TL;DR: Single-agent trastuzumab is active and well tolerated as first-line treatment of women with metastatic breast cancer with HER2 3+ overexpression by IHC or gene amplification by FISH.
Journal ArticleDOI
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Kathy D. Miller,Molin Wang,Julie Gralow,Maura N. Dickler,Melody A. Cobleigh,Edith A. Perez,Tamara Shenkier,David Cella,David Cella,Nancy E. Davidson +9 more
TL;DR: Initial therapy of metastatic breast cancer with paclitaxel plus bevacizumab prolongs progression-free survival, but not overall survival, as compared with pac litaxel alone.
Journal ArticleDOI
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
Melody A. Cobleigh,Charles L. Vogel,Debasish Tripathy,Nicholas J. Robert,Susy Scholl,Louis Fehrenbacher,Janet M. Wolter,Virginia Paton,Steven Shak,Gracie Lieberman,Dennis J. Slamon +10 more
TL;DR: Recombinant humanized anti-HER2 monoclonal antibody, administered as a single agent, produces durable objective responses and is well tolerated by women with HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.
Journal ArticleDOI
Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument.
Marianne J. Brady,David Cella,F. Mo,Amy E. Bonomi,David S. Tulsky,Stephen Lloyd,S Deasy,Melody A. Cobleigh,G Shiomoto +8 more
TL;DR: The FACT-B is appropriate for use in oncology clinical trials, as well as in clinical practice, and demonstrates ease of administration, brevity, reliability, validity, and sensitivity to change.
Journal ArticleDOI
Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer
Kathy D. Miller,Linnea I. Chap,Frankie A. Holmes,Melody A. Cobleigh,P. Kelly Marcom,Louis Fehrenbacher,Maura N. Dickler,Beth Overmoyer,James D. Reimann,Amy P. Sing,Virginia K. Langmuir,Hope S. Rugo +11 more
TL;DR: Although the addition of bevacizumab to capecitabine produced a significant increase in response rates, this did not translate into improved PFS or overall survival.